New drug JNJ-95437446 enters human testing for Hard-to-Treat cancers

NCT ID NCT07107230

Recruiting now Disease control Sponsor: Janssen Research & Development, LLC Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jul 07, 2026 · Updated 3 times

Summary

This early-stage trial tests a new drug called JNJ-95437446 in people with advanced solid tumors, including colorectal cancer, that have not responded to standard treatments. The study has two parts: first, finding a safe dose, and second, checking safety more closely in a larger group. About 380 participants will take part to see if the drug can shrink tumors and what side effects it may cause.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: JNJ-95437446
What this could lead to: If successful, this could point toward a new treatment option for people with advanced solid tumors that have not responded to other therapies.
What could go wrong: This is an early Phase 1 trial focused on safety and dosing, not yet on effectiveness. The drug may cause side effects or not shrink tumors. Results may not apply to all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for COLORECTAL CARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

colorectal carcinoma colorectal neoplasm head and neck squamous cell carcinoma non-small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

COLORECTAL NEOPLASMS

Contacts and locations

Locations

Columbia University Medical Center Herbert Irving Pavilion
RECRUITING

New York, New York, 10032, United States
Florida Cancer Specialists
RECRUITING

Sarasota, Florida, 34232, United States
Hosp Univ Fund Jimenez Diaz
RECRUITING

Madrid, 28040, Spain
Hosp Univ Hm Sanchinarro
RECRUITING

Madrid, 28050, Spain
Hosp Univ Vall D Hebron
RECRUITING

Barcelona, 8035, Spain
Hosp. Univ. 12 de Octubre
RECRUITING

Madrid, 28041, Spain
NEXT Oncology
RECRUITING

Fairfax, Virginia, 22031, United States
Samsung Medical Center
RECRUITING

Seoul, 06351, South Korea
Severance Hospital Yonsei University Health System
RECRUITING

Seoul, 03722, South Korea
Tennessee Oncology
RECRUITING

Nashville, Tennessee, 37203, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.